CYP2C19

The clopidogrel switch.

CYP2C19 is a hepatic cytochrome P450 enzyme that performs oxidative metabolism on a focused but high-stakes set of drugs. For one of them — clopidogrel — it works as an activator: clopidogrel is an inactive prodrug, and CYP2C19 catalyzes a key step that converts it into the active metabolite that blocks platelet aggregation. No active metabolite, no antiplatelet effect.

For most of its other substrates, CYP2C19 inactivates the parent drug: proton-pump inhibitors (omeprazole, lansoprazole, pantoprazole), the antidepressants citalopram, escitalopram and sertraline, the benzodiazepine diazepam, and the antifungal voriconazole. Here the clinical implication runs the other way — a poor metabolizer accumulates higher drug levels, which can mean better acid suppression with a PPI but a greater risk of side effects with an antidepressant or voriconazole.

Unlike CYP2D6, CYP2C19 sits in a structurally simpler region of chromosome 10 — there is no common whole-gene duplication or deletion and no high-similarity pseudogene to confuse genotyping. That makes CYP2C19 one of the more tractable pharmacogenes to read from a SNP array.

Star alleles, not single SNPs.

CYP2C19 is described using star-allele haplotype nomenclature. Each star allele is a defined haplotype with a known activity level. The most clinically relevant alleles globally:

Each person carries two alleles. The combination defines a phenotype:

• Poor metabolizer (PM) — two no-function alleles (e.g. *2/*2, *2/*3).
• Intermediate metabolizer (IM) — one normal and one no-function allele (e.g. *1/*2).
• Normal metabolizer (NM) — two normal-function alleles (*1/*1).
• Rapid metabolizer (RM) — one normal and one increased-function allele (*1/*17).
• Ultra-rapid metabolizer (UM) — two increased-function alleles (*17/*17).

One of the few genes with an FDA boxed warning.

CYP2C19 has formal, peer-reviewed dosing guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG). These are clinical recommendations, not speculation. Examples:

• Clopidogrel (Plavix): CPIC's 2022 guideline recommends an alternative antiplatelet (prasugrel or ticagrelor) for poor and intermediate metabolizers undergoing percutaneous coronary intervention for acute coronary syndromes, because they form less active metabolite and have higher rates of stent thrombosis and cardiovascular events. Clopidogrel carries an FDA boxed warning about reduced effectiveness in poor metabolizers.
• Proton-pump inhibitors: CPIC notes that normal/rapid/ultra-rapid metabolizers clear PPIs faster and may need a higher dose for reflux or H. pylori eradication, while poor metabolizers reach higher drug levels.
• SSRIs (citalopram, escitalopram, sertraline): CPIC provides phenotype-based dosing — ultra-rapid metabolizers may have reduced response; poor metabolizers reach higher concentrations.
• Voriconazole: CPIC recommends an alternative antifungal for poor metabolizers (toxicity risk) and dose adjustment or alternative for ultra-rapid metabolizers (subtherapeutic levels).

Primary sources: CPIC — CYP2C19 gene page; Lee et al., Clin Pharmacol Ther 2022 (CPIC clopidogrel guideline update); PharmGKB CYP2C19; PharmVar CYP2C19.

What consumer arrays do — and don't — tell you about CYP2C19.

CYP2C19 is one of the friendlier pharmacogenes for consumer raw data, because the two most important alleles are tagged by single, commonly genotyped SNPs and there is no copy-number or pseudogene complication. What you can usually look up:

• rs4244285 (*2 marker) — almost always genotyped. Two A alleles indicate a likely *2/*2 poor metabolizer (subject to phasing).
• rs12248560 (*17 marker) — usually genotyped. Important for rapid/ultra-rapid status, especially in European and African ancestry.
• rs4986893 (*3 marker) — sometimes genotyped; matters mainly in East Asian populations.

The honest limits still apply: a raw file gives genotypes at single positions, not a phased, clinically validated star-allele call, and it will miss rarer alleles. For a real decision about clopidogrel after a stent, the appropriate tool is a CPIC-aware clinical pharmacogenomic test ordered through a clinician — not a consumer file. But of the major drug-metabolism genes, CYP2C19 is the one where your raw data comes closest to a useful answer.